Cancer genetics service provision: A comparison of seven European centres

P. Hopwood, C. J. Van Asperen, G. Borreani, P. Bourret, M. Decruyenaere, S. Dishon, F. Eisinger, D. G R Evans, G. Evers-Kiebooms, L. Gangeri, L. Hagoel, E. Legius, I. Nippert, G. Rennert, B. Schlegelberger, C. Sevilla, H. Sobol, A. Tibben, M. Welkenhuysen, C. Julian-Reynier

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: To conduct a survey in seven European cancer genetics centres to compare service provision, organisation and practices for familial breast and colon cancer consultations and testing. Information was obtained on aspects of services both nationally and locally. Methods: A detailed survey questionnaire was adapted collaboratively to obtain the required information. Initial survey data were collected within each centre and interim results were discussed at two European Workshops. Where differences in practice existed, details were clarified to ensure accuracy and adequacy of information. Participating centres were Haifa (Israel), Hannover (Germany), Leiden (The Netherlands), Leuven (Belgium), Manchester (UK), Marseille (France) and Milan (Italy), representing countries with populations ranging from 6.5 to 80 million. Results: The European countries diverged in regard to the number of cancer genetics centres nationally (from 8 in Belgium to 37 in France), and the average population served by each centre (from 0.59 million in Israel to 3.32 million in Italy). All centres offered free care at the point of access, but referral to specialist care varied according to national health care provision. At a centre level, staff roles varied due to differences in training and health care provision. The annual number of counsellees seen in each participating centre ranged from 200 to over 1,700. Access to breast surveillance or bowel screening varied between countries, again reflecting differences in medical care pathways. These countries converged in regard to the wide availability of professional bodies and published guidelines promoting aspects of service provision. Similarities between centres included provision of a multidisciplinary team, with access to psychological support, albeit with varying degrees of integration. All services were dominated (70-90%) by referrals from families with an increased risk of breast cancer despite wide variation in referral patterns. Collection of pedigree data and risk assessment strategies were broadly similar, and centres used comparable genetic testing protocols. Average consultation times ranged between 45 and 90 min. All centres had access to a laboratory offering DNA testing for breast and bowel cancer-predisposing genes, although testing rates varied, reflecting the stage of service development and the type of population. Israel offered the highest number of genetic tests for breast cancer susceptibility because of the existence of specific founder mutations, in part explaining why the cancer genetics service in Haifa differed most from the other six. Conclusion: Despite considerable differences in service organisation, there were broad similarities in the provision of cancer genetic services in the centres surveyed.

Original languageEnglish
Pages (from-to)192-205
Number of pages14
JournalCommunity Genetics
Volume6
Issue number4
DOIs
Publication statusPublished - 2003

Fingerprint

Genetic Services
Referral and Consultation
Israel
Belgium
Neoplasms
Breast Neoplasms
Colonic Neoplasms
Italy
France
Point-of-Care Systems
Population
Delivery of Health Care
Neoplasm Genes
Genetic Testing
Pedigree
Netherlands
Germany
Breast
Guidelines
Psychology

Keywords

  • Breast cancer risk
  • Cancer genetic services
  • Colorectal cancer risk
  • European cancer genetics centres

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Hopwood, P., Van Asperen, C. J., Borreani, G., Bourret, P., Decruyenaere, M., Dishon, S., ... Julian-Reynier, C. (2003). Cancer genetics service provision: A comparison of seven European centres. Community Genetics, 6(4), 192-205. https://doi.org/10.1159/000079381

Cancer genetics service provision : A comparison of seven European centres. / Hopwood, P.; Van Asperen, C. J.; Borreani, G.; Bourret, P.; Decruyenaere, M.; Dishon, S.; Eisinger, F.; Evans, D. G R; Evers-Kiebooms, G.; Gangeri, L.; Hagoel, L.; Legius, E.; Nippert, I.; Rennert, G.; Schlegelberger, B.; Sevilla, C.; Sobol, H.; Tibben, A.; Welkenhuysen, M.; Julian-Reynier, C.

In: Community Genetics, Vol. 6, No. 4, 2003, p. 192-205.

Research output: Contribution to journalArticle

Hopwood, P, Van Asperen, CJ, Borreani, G, Bourret, P, Decruyenaere, M, Dishon, S, Eisinger, F, Evans, DGR, Evers-Kiebooms, G, Gangeri, L, Hagoel, L, Legius, E, Nippert, I, Rennert, G, Schlegelberger, B, Sevilla, C, Sobol, H, Tibben, A, Welkenhuysen, M & Julian-Reynier, C 2003, 'Cancer genetics service provision: A comparison of seven European centres', Community Genetics, vol. 6, no. 4, pp. 192-205. https://doi.org/10.1159/000079381
Hopwood P, Van Asperen CJ, Borreani G, Bourret P, Decruyenaere M, Dishon S et al. Cancer genetics service provision: A comparison of seven European centres. Community Genetics. 2003;6(4):192-205. https://doi.org/10.1159/000079381
Hopwood, P. ; Van Asperen, C. J. ; Borreani, G. ; Bourret, P. ; Decruyenaere, M. ; Dishon, S. ; Eisinger, F. ; Evans, D. G R ; Evers-Kiebooms, G. ; Gangeri, L. ; Hagoel, L. ; Legius, E. ; Nippert, I. ; Rennert, G. ; Schlegelberger, B. ; Sevilla, C. ; Sobol, H. ; Tibben, A. ; Welkenhuysen, M. ; Julian-Reynier, C. / Cancer genetics service provision : A comparison of seven European centres. In: Community Genetics. 2003 ; Vol. 6, No. 4. pp. 192-205.
@article{8d143a6bdd8f4c258b74964216d0203d,
title = "Cancer genetics service provision: A comparison of seven European centres",
abstract = "Objective: To conduct a survey in seven European cancer genetics centres to compare service provision, organisation and practices for familial breast and colon cancer consultations and testing. Information was obtained on aspects of services both nationally and locally. Methods: A detailed survey questionnaire was adapted collaboratively to obtain the required information. Initial survey data were collected within each centre and interim results were discussed at two European Workshops. Where differences in practice existed, details were clarified to ensure accuracy and adequacy of information. Participating centres were Haifa (Israel), Hannover (Germany), Leiden (The Netherlands), Leuven (Belgium), Manchester (UK), Marseille (France) and Milan (Italy), representing countries with populations ranging from 6.5 to 80 million. Results: The European countries diverged in regard to the number of cancer genetics centres nationally (from 8 in Belgium to 37 in France), and the average population served by each centre (from 0.59 million in Israel to 3.32 million in Italy). All centres offered free care at the point of access, but referral to specialist care varied according to national health care provision. At a centre level, staff roles varied due to differences in training and health care provision. The annual number of counsellees seen in each participating centre ranged from 200 to over 1,700. Access to breast surveillance or bowel screening varied between countries, again reflecting differences in medical care pathways. These countries converged in regard to the wide availability of professional bodies and published guidelines promoting aspects of service provision. Similarities between centres included provision of a multidisciplinary team, with access to psychological support, albeit with varying degrees of integration. All services were dominated (70-90{\%}) by referrals from families with an increased risk of breast cancer despite wide variation in referral patterns. Collection of pedigree data and risk assessment strategies were broadly similar, and centres used comparable genetic testing protocols. Average consultation times ranged between 45 and 90 min. All centres had access to a laboratory offering DNA testing for breast and bowel cancer-predisposing genes, although testing rates varied, reflecting the stage of service development and the type of population. Israel offered the highest number of genetic tests for breast cancer susceptibility because of the existence of specific founder mutations, in part explaining why the cancer genetics service in Haifa differed most from the other six. Conclusion: Despite considerable differences in service organisation, there were broad similarities in the provision of cancer genetic services in the centres surveyed.",
keywords = "Breast cancer risk, Cancer genetic services, Colorectal cancer risk, European cancer genetics centres",
author = "P. Hopwood and {Van Asperen}, {C. J.} and G. Borreani and P. Bourret and M. Decruyenaere and S. Dishon and F. Eisinger and Evans, {D. G R} and G. Evers-Kiebooms and L. Gangeri and L. Hagoel and E. Legius and I. Nippert and G. Rennert and B. Schlegelberger and C. Sevilla and H. Sobol and A. Tibben and M. Welkenhuysen and C. Julian-Reynier",
year = "2003",
doi = "10.1159/000079381",
language = "English",
volume = "6",
pages = "192--205",
journal = "Community Genetics",
issn = "1422-2795",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Cancer genetics service provision

T2 - A comparison of seven European centres

AU - Hopwood, P.

AU - Van Asperen, C. J.

AU - Borreani, G.

AU - Bourret, P.

AU - Decruyenaere, M.

AU - Dishon, S.

AU - Eisinger, F.

AU - Evans, D. G R

AU - Evers-Kiebooms, G.

AU - Gangeri, L.

AU - Hagoel, L.

AU - Legius, E.

AU - Nippert, I.

AU - Rennert, G.

AU - Schlegelberger, B.

AU - Sevilla, C.

AU - Sobol, H.

AU - Tibben, A.

AU - Welkenhuysen, M.

AU - Julian-Reynier, C.

PY - 2003

Y1 - 2003

N2 - Objective: To conduct a survey in seven European cancer genetics centres to compare service provision, organisation and practices for familial breast and colon cancer consultations and testing. Information was obtained on aspects of services both nationally and locally. Methods: A detailed survey questionnaire was adapted collaboratively to obtain the required information. Initial survey data were collected within each centre and interim results were discussed at two European Workshops. Where differences in practice existed, details were clarified to ensure accuracy and adequacy of information. Participating centres were Haifa (Israel), Hannover (Germany), Leiden (The Netherlands), Leuven (Belgium), Manchester (UK), Marseille (France) and Milan (Italy), representing countries with populations ranging from 6.5 to 80 million. Results: The European countries diverged in regard to the number of cancer genetics centres nationally (from 8 in Belgium to 37 in France), and the average population served by each centre (from 0.59 million in Israel to 3.32 million in Italy). All centres offered free care at the point of access, but referral to specialist care varied according to national health care provision. At a centre level, staff roles varied due to differences in training and health care provision. The annual number of counsellees seen in each participating centre ranged from 200 to over 1,700. Access to breast surveillance or bowel screening varied between countries, again reflecting differences in medical care pathways. These countries converged in regard to the wide availability of professional bodies and published guidelines promoting aspects of service provision. Similarities between centres included provision of a multidisciplinary team, with access to psychological support, albeit with varying degrees of integration. All services were dominated (70-90%) by referrals from families with an increased risk of breast cancer despite wide variation in referral patterns. Collection of pedigree data and risk assessment strategies were broadly similar, and centres used comparable genetic testing protocols. Average consultation times ranged between 45 and 90 min. All centres had access to a laboratory offering DNA testing for breast and bowel cancer-predisposing genes, although testing rates varied, reflecting the stage of service development and the type of population. Israel offered the highest number of genetic tests for breast cancer susceptibility because of the existence of specific founder mutations, in part explaining why the cancer genetics service in Haifa differed most from the other six. Conclusion: Despite considerable differences in service organisation, there were broad similarities in the provision of cancer genetic services in the centres surveyed.

AB - Objective: To conduct a survey in seven European cancer genetics centres to compare service provision, organisation and practices for familial breast and colon cancer consultations and testing. Information was obtained on aspects of services both nationally and locally. Methods: A detailed survey questionnaire was adapted collaboratively to obtain the required information. Initial survey data were collected within each centre and interim results were discussed at two European Workshops. Where differences in practice existed, details were clarified to ensure accuracy and adequacy of information. Participating centres were Haifa (Israel), Hannover (Germany), Leiden (The Netherlands), Leuven (Belgium), Manchester (UK), Marseille (France) and Milan (Italy), representing countries with populations ranging from 6.5 to 80 million. Results: The European countries diverged in regard to the number of cancer genetics centres nationally (from 8 in Belgium to 37 in France), and the average population served by each centre (from 0.59 million in Israel to 3.32 million in Italy). All centres offered free care at the point of access, but referral to specialist care varied according to national health care provision. At a centre level, staff roles varied due to differences in training and health care provision. The annual number of counsellees seen in each participating centre ranged from 200 to over 1,700. Access to breast surveillance or bowel screening varied between countries, again reflecting differences in medical care pathways. These countries converged in regard to the wide availability of professional bodies and published guidelines promoting aspects of service provision. Similarities between centres included provision of a multidisciplinary team, with access to psychological support, albeit with varying degrees of integration. All services were dominated (70-90%) by referrals from families with an increased risk of breast cancer despite wide variation in referral patterns. Collection of pedigree data and risk assessment strategies were broadly similar, and centres used comparable genetic testing protocols. Average consultation times ranged between 45 and 90 min. All centres had access to a laboratory offering DNA testing for breast and bowel cancer-predisposing genes, although testing rates varied, reflecting the stage of service development and the type of population. Israel offered the highest number of genetic tests for breast cancer susceptibility because of the existence of specific founder mutations, in part explaining why the cancer genetics service in Haifa differed most from the other six. Conclusion: Despite considerable differences in service organisation, there were broad similarities in the provision of cancer genetic services in the centres surveyed.

KW - Breast cancer risk

KW - Cancer genetic services

KW - Colorectal cancer risk

KW - European cancer genetics centres

UR - http://www.scopus.com/inward/record.url?scp=4444282375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444282375&partnerID=8YFLogxK

U2 - 10.1159/000079381

DO - 10.1159/000079381

M3 - Article

C2 - 15331865

AN - SCOPUS:4444282375

VL - 6

SP - 192

EP - 205

JO - Community Genetics

JF - Community Genetics

SN - 1422-2795

IS - 4

ER -